ArticleDiscover oncology2026
KIF20A suppresses ferroptosis in HCC through HMOX1/SLC7A11/GPX4 signaling pathway.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation, has been increasingly implicated in cancer progression. However, the mechanism of carcinoma progression is still unclear, especially in hepatocellular carcinoma (HCC). In this study, we identified several ferroptosis-related genes by using bioinformatics analysis, including KIF20A. In PLC and SNU449 HCC cell lines, the knockdown of KIF20A could decrease the proliferation and increase the levels of MDA, ferrous ions, and ROS. In Hep3B and SNU 398 HCC cell lines, the overexpression of KIF20A enhanced the proliferative capacity and reduced the levels of MDA, ferrous ions, and ROS. To explore downstream molecular targets, this study performed RNA-sequencing following KIF20A knockdown, identifying HMOX1 as a key downstream target gene. Knockdown of KIF20A upregulates the expression of HMOX1 at both mRNA and protein levels. Conversely, overexpression of this gene yielded opposite results. Furthermore, our findings indicate that KIF20A inhibits ferroptosis in HCC cells via the HMOX1/SLC7A11/GPX4 pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.